Hostname: page-component-745bb68f8f-hvd4g Total loading time: 0 Render date: 2025-01-10T09:17:13.575Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacokinetics and psychotropic drugs

Published online by Cambridge University Press:  09 July 2009

Stephen H. Curry
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Psychological Medicine , Volume 8 , Issue 2 , May 1978 , pp. 177 - 180
Copyright
Copyright © Cambridge University Press 1978

References

Åsberg, M., Cronholm, B., Sjöqvist, F. & Tuck, D. (1971). Relationship between plasma level and therapeutic effect of nortriptyline. British Medical Journal iii, 331–334.CrossRefGoogle Scholar
Boullin, D. J., Woods, H. F., Grimes, R. P. J., Grahame-Smith, D. G., Wiles, D. H., Gelder, M. G. & Kolakowska, T. (1975). Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. British Journal of Clinical Pharmacology 2, 29–35.CrossRefGoogle ScholarPubMed
Brodie, B. B. (1967). Physicochemical and biochemical aspects of pharmacology. Journal of the American Medical Association 202, 600–609.CrossRefGoogle ScholarPubMed
Curry, S. H. (1968). Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas–liquid chromatography with an electron-capture detector. Analytical Chemistry 40, 1251–1255.CrossRefGoogle ScholarPubMed
Curry, S. H. (1976). Gas-chromatographic methods for the study of chlorpromazine and some of its metabolites in human plasma. Psychopharmacology Communications 2, 1–15.Google Scholar
Curry, S. H. & Brodie, B. B. (1967). Estimation of nanogram quantities of chlorpromazine (CPZ) in plasma using gas–liquid chromatography (GLC) with an electron-capture detector. Federation Proceedings 26, 761.Google Scholar
Curry, S. H. & Evans, S. (1976). A note on the assay of chlorpromazine N-oxide and its sulphoxide in plasma and urine. Journal of Pharmacy and Pharmacology 28, 467–468.CrossRefGoogle ScholarPubMed
Davidson, J. D., Terry, L. L. & Sjoerdsma, A. (1957). Action and metabolism of chlorpromazine sulfoxide in man. Journal of Pharmacology and Experimental Therapeutics 121, 8–12.Google ScholarPubMed
Garattini, S., Marcucci, F., Morselli, P. L. & Mussini, E. (1973). The significance of measuring blood levels of benzodiazepines. In Biological Effects of Drugs in Relation to their Plasma Concentrations (ed. Davies, D. S. and Prichard, B. N. C.), pp. 211–225. Macmillan: London.Google Scholar
Hammer, W. & Brodie, B. B. (1967). Application of isotope derivative technique to assay of secondary amines. Estimation of desipramine by acetylation with H3 acetic anhydride. Journal of Pharmacology and Experimental Therapeutics 157, 503–508.Google ScholarPubMed
Kolakowska, T., Wiles, D. H., Gelder, M. G. & McNeilly, A. S. (1975). Correlation between plasma levels of prolactin and chlorpromazine in psychiatric patients. Psychological Medicine 5, 214–216.CrossRefGoogle ScholarPubMed
Loga, S., Curry, S. H. & Lader, M. H. (1975). Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. British Journal of Clinical Pharmacology 2, 197–208.CrossRefGoogle ScholarPubMed
Mackay, A. V. P., Healey, A. F. & Baker, J. (1974). The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics. British Journal of Clinical Pharmacology 1, 425–430.CrossRefGoogle Scholar
Moody, J. P., Tait, A. C. & Todrick, A. (1967). Plasma levels of imipramine and desmethylimipramine during therapy. British Journal of Psychiatry 113, 183–193.CrossRefGoogle ScholarPubMed
Sakalis, G., Curry, S. H., Mould, G. P. & Lader, M. H. (1972). Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clinical Pharmacology and Therapeutics 13, 931–946.CrossRefGoogle ScholarPubMed
Sakalis, G., Chan, T. L., Gershon, S. & Park, S. (1973). The possible role of metabolites in therapeutic response to chlorpromazine treatment. Psychopharmacologia (Berlin) 32, 279–284.CrossRefGoogle ScholarPubMed
Sakalis, G., Chan, T. L., Sathananthan, G., Schooler, N., Goldberg, S. & Gershon, S. (1977). Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios. Communications in Psychopharmacology 1, 157–166.Google ScholarPubMed
Schou, M. (1969). Lithium: relation between clinical effect of the drug and its absorption, distribution and excretion. In The Present Status of Psychotropic Drugs (ed. Cerletti, A. and Bove, J. J.), pp. 120–122. Excerpta Medica: Amsterdam.Google Scholar